AU2021343534A1 - TREATMENT OF NF-κB-MEDIATED DISEASE - Google Patents

TREATMENT OF NF-κB-MEDIATED DISEASE Download PDF

Info

Publication number
AU2021343534A1
AU2021343534A1 AU2021343534A AU2021343534A AU2021343534A1 AU 2021343534 A1 AU2021343534 A1 AU 2021343534A1 AU 2021343534 A AU2021343534 A AU 2021343534A AU 2021343534 A AU2021343534 A AU 2021343534A AU 2021343534 A1 AU2021343534 A1 AU 2021343534A1
Authority
AU
Australia
Prior art keywords
human patient
day
vamorolone
muscular dystrophy
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021343534A
Other languages
English (en)
Other versions
AU2021343534A9 (en
Inventor
Jesse DAMSKER
Eric Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reveragen Biopharma Inc
Original Assignee
Reveragen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reveragen Biopharma Inc filed Critical Reveragen Biopharma Inc
Publication of AU2021343534A1 publication Critical patent/AU2021343534A1/en
Publication of AU2021343534A9 publication Critical patent/AU2021343534A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021343534A 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE Pending AU2021343534A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US63/081,073 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US63/195,473 2021-06-01
US202163214908P 2021-06-25 2021-06-25
US63/214,908 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (2)

Publication Number Publication Date
AU2021343534A1 true AU2021343534A1 (en) 2023-05-11
AU2021343534A9 AU2021343534A9 (en) 2024-10-17

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021343534A Pending AU2021343534A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Country Status (9)

Country Link
US (2) US20220184098A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213855A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543439A (cg-RX-API-DMAC10.html)
KR (1) KR20230092905A (cg-RX-API-DMAC10.html)
AU (1) AU2021343534A1 (cg-RX-API-DMAC10.html)
CA (1) CA3170698A1 (cg-RX-API-DMAC10.html)
IL (1) IL301500A (cg-RX-API-DMAC10.html)
MX (1) MX2023003258A (cg-RX-API-DMAC10.html)
WO (1) WO2022061287A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2785351A4 (en) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc NONTHORMONAL STEROID MODULATORS OF NF-KB FOR THE TREATMENT OF DISEASES
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
US11382922B2 (en) * 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
MX2023003258A (es) 2023-05-08
US20220184098A1 (en) 2022-06-16
EP4213855A4 (en) 2024-10-23
EP4213855A1 (en) 2023-07-26
US20240139210A1 (en) 2024-05-02
IL301500A (en) 2023-05-01
WO2022061287A1 (en) 2022-03-24
CA3170698A1 (en) 2022-03-24
KR20230092905A (ko) 2023-06-26
JP2023543439A (ja) 2023-10-16

Similar Documents

Publication Publication Date Title
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
TW202128183A (zh) 用於治療多種病症之方法及組成物
JP7819094B2 (ja) ヒトアミノステロールent-03化合物、それを含む関連組成物、およびそれを使用する方法
US20240139210A1 (en) Treatment of nf-kb-mediated disease
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
AU2023220976A1 (en) Neuroactive steroids for treatment of cns-related disorders
JP7607577B2 (ja) ピリダジノンtrpc5阻害剤の噴霧乾燥された製剤
JP2023539567A (ja) 神経活性ステロイドを含有する医薬組成物及びその使用
KR20150119227A (ko) 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
US20240299416A1 (en) TREATMENT OF NF-kB-MEDIATED DISEASE
AU2024204716A1 (en) Treatment of alopecia areata
US20240226117A1 (en) Treatment of congenital adrenal hypoplasia
CN116507338A (zh) NF-κB介导的疾病的治疗
AU2019386235A1 (en) Montelukast for the treatment of erosive hand osteoarthritis
JP2024527992A (ja) 神経刺激性ステロイドの結晶形
Nishizawa et al. Importance of long-term motor function evaluation after prednisolone treatment for Duchenne muscular dystrophy
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний

Legal Events

Date Code Title Description
SREP Specification republished